Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daily rifapentine + isoniazid (1HP) dose-finding and safety study for tuberculosis prevention in children with and without HIV
PACTR202602859785397Phase 2Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rifapentine and isoniazid in Tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: All adverse events through Day 28, Grade 3 or higher adverse events through Day 28 and 3 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
rifapentineisoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202602859785397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202602859785397.